Precisely Restoring Immune Balance to Treat Autoimmune Diseases

AltruBio has introduced an antibody that targets a novel regulator of the immune system, an immune checkpoint inhibitor, to precisely remove chronically over-activated T-cells partly responsible for causing autoimmune disease.

Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’s pipeline focuses on depleting unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases.

The Company’s pipeline includes programs aimed at combatting acute Graft Versus Host Disease and Ulcerative Colitis.